Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

128 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2018.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 108 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 34,359,383 shares of 104,661,494 outstanding shares and own 33% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (4,015,343 shares), JPMORGAN CHASE & CO (3,646,591 shares), Essex Woodlands Management, Inc. (3,342,047 shares), BlackRock Inc. (3,194,983 shares), FRANKLIN RESOURCES INC (2,549,735 shares), Bank of New York Mellon Corp (2,464,617 shares), ArrowMark Colorado Holdings LLC (2,243,655 shares), ALLIANCEBERNSTEIN L.P. (1,651,949 shares), NovaQuest Capital Management, L.L.C. (1,558,426 shares), and Vanguard Group Inc (1,506,795 shares).
This table shows the top 108 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.